JP2004515218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004515218A5 JP2004515218A5 JP2002505815A JP2002505815A JP2004515218A5 JP 2004515218 A5 JP2004515218 A5 JP 2004515218A5 JP 2002505815 A JP2002505815 A JP 2002505815A JP 2002505815 A JP2002505815 A JP 2002505815A JP 2004515218 A5 JP2004515218 A5 JP 2004515218A5
- Authority
- JP
- Japan
- Prior art keywords
- rsv
- gene
- antigenome
- genome
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000725643 Respiratory syncytial virus Species 0.000 description 316
- 108090000623 proteins and genes Proteins 0.000 description 143
- 108091033319 polynucleotide Proteins 0.000 description 101
- 102000040430 polynucleotide Human genes 0.000 description 101
- 239000002157 polynucleotide Substances 0.000 description 101
- 208000015181 infectious disease Diseases 0.000 description 90
- 230000002458 infectious effect Effects 0.000 description 89
- 108090000288 Glycoproteins Proteins 0.000 description 62
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 29
- 101710144128 Non-structural protein 2 Proteins 0.000 description 29
- 101710199667 Nuclear export protein Proteins 0.000 description 29
- 241000711920 Human orthopneumovirus Species 0.000 description 26
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 25
- 101710128560 Initiator protein NS1 Proteins 0.000 description 25
- 101710144127 Non-structural protein 1 Proteins 0.000 description 25
- 241000711895 Bovine orthopneumovirus Species 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 101150082239 G gene Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 101150107578 SH gene Proteins 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241000712079 Measles morbillivirus Species 0.000 description 5
- 101150033828 NS1 gene Proteins 0.000 description 5
- 101150095629 NS2 gene Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 241000724205 Rice stripe tenuivirus Species 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 241000711950 Filoviridae Species 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 3
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 3
- 102100024407 Jouberin Human genes 0.000 description 3
- 241000713112 Orthobunyavirus Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- -1 M2ORF2 Proteins 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 101150036080 at gene Proteins 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 101150034814 F gene Proteins 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- 101000719019 Homo sapiens Glutamyl aminopeptidase Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 108700005307 Human papillomavirus HPV L1 Proteins 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- 241001559187 Human rubulavirus 2 Species 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 101150046652 M2 gene Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101150009852 ORF2 gene Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108010015329 Respiratory syncytial virus G glycoprotein Proteins 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 108700023453 human respiratory syncytial virus F Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012259 partial gene deletion Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21370800P | 2000-06-23 | 2000-06-23 | |
| PCT/US2001/020107 WO2002000693A2 (en) | 2000-06-23 | 2001-06-22 | Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004515218A JP2004515218A (ja) | 2004-05-27 |
| JP2004515218A5 true JP2004515218A5 (enExample) | 2008-08-21 |
Family
ID=22796187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002505815A Pending JP2004515218A (ja) | 2000-06-23 | 2001-06-22 | プロモータへ隣接する遺伝子から保護抗原を発現する呼吸器系合胞体ウイルスワクチン |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1294858B1 (enExample) |
| JP (1) | JP2004515218A (enExample) |
| KR (1) | KR100899030B1 (enExample) |
| CN (1) | CN1468301A (enExample) |
| AT (1) | ATE416251T1 (enExample) |
| AU (3) | AU6870901A (enExample) |
| BR (1) | BRPI0112276B8 (enExample) |
| CA (1) | CA2413786A1 (enExample) |
| DE (1) | DE60136811D1 (enExample) |
| ES (1) | ES2317914T3 (enExample) |
| IL (1) | IL153530A0 (enExample) |
| MX (1) | MXPA02012818A (enExample) |
| WO (1) | WO2002000693A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003530073A (ja) * | 1999-07-09 | 2003-10-14 | アメリカ合衆国 | 弱毒化されたヒト−ウシキメラ呼吸器合胞体ウィルスワクチンの製造 |
| WO2008094200A2 (en) * | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc | Chimeric virus-like particles |
| WO2008094197A2 (en) | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| WO2011056899A2 (en) | 2009-11-03 | 2011-05-12 | Ligocyte Pharmaceuticals, Inc. | Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps |
| CN105200069A (zh) * | 2015-10-16 | 2015-12-30 | 北京交通大学 | 基于rna聚合酶ⅰ的rsv微型复制基因组及其应用 |
| CA3007474A1 (en) * | 2015-12-11 | 2017-06-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant respiratory syncytial virus strains comprising ns1 and ns2 gene shifts |
| CN110229219B (zh) * | 2019-06-21 | 2021-03-30 | 中国科学院武汉病毒研究所 | 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2112220A3 (en) * | 1996-07-15 | 2010-01-06 | The Government of the United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
-
2001
- 2001-06-22 EP EP01946696A patent/EP1294858B1/en not_active Expired - Lifetime
- 2001-06-22 BR BR0112276-2 patent/BRPI0112276B8/pt not_active IP Right Cessation
- 2001-06-22 AU AU6870901A patent/AU6870901A/xx active Pending
- 2001-06-22 KR KR1020027017577A patent/KR100899030B1/ko not_active Expired - Fee Related
- 2001-06-22 JP JP2002505815A patent/JP2004515218A/ja active Pending
- 2001-06-22 IL IL15353001A patent/IL153530A0/xx not_active IP Right Cessation
- 2001-06-22 AU AU2001268709A patent/AU2001268709B2/en not_active Ceased
- 2001-06-22 DE DE60136811T patent/DE60136811D1/de not_active Expired - Lifetime
- 2001-06-22 CA CA002413786A patent/CA2413786A1/en not_active Abandoned
- 2001-06-22 WO PCT/US2001/020107 patent/WO2002000693A2/en not_active Ceased
- 2001-06-22 MX MXPA02012818A patent/MXPA02012818A/es active IP Right Grant
- 2001-06-22 ES ES01946696T patent/ES2317914T3/es not_active Expired - Lifetime
- 2001-06-22 CN CNA018143628A patent/CN1468301A/zh active Pending
- 2001-06-22 AT AT01946696T patent/ATE416251T1/de not_active IP Right Cessation
-
2006
- 2006-12-22 AU AU2006252238A patent/AU2006252238A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Collins et al. | New generation live vaccines against human respiratory syncytial virus designed by reverse genetics | |
| Karron et al. | Live-attenuated respiratory syncytial virus vaccines | |
| KR102401247B1 (ko) | Rsv에 대한 백신 | |
| TWI624545B (zh) | 抗ｒｓｖ疫苗 | |
| JP2003516148A5 (enExample) | ||
| Skiadopoulos et al. | Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp 45) human parainfluenza virus 3 candidate vaccine | |
| US20090041725A1 (en) | Replication-Deficient RNA Viruses as Vaccines | |
| US20210330782A1 (en) | Genetically stable live attenuated respiratory syncytial virus vaccine and its production | |
| JP2003504064A5 (enExample) | ||
| ES2312347T3 (es) | Vacunas atenuadas quimericas humano-bovino del virus parainfluenza (piv). | |
| CA2378497A1 (en) | Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene | |
| EP3868874A1 (en) | Recombinant rsv live vaccine strain and production method therefor | |
| Skiadopoulos et al. | Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts | |
| Skiadopoulos et al. | Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes | |
| JP2004515218A5 (enExample) | ||
| US7250171B1 (en) | Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein | |
| US20160120974A1 (en) | Semi-live respiratory syncytial virus vaccine | |
| WO2012085936A2 (en) | Recombinant respiratory syncytial virus plasmids and vaccines | |
| US7201907B1 (en) | Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines | |
| US7314631B1 (en) | Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV) | |
| US7632508B2 (en) | Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines | |
| JP2024536236A (ja) | 組み換えられた弱毒化ｒｓｖ生ワクチン及びその製造方法 | |
| US20100330120A1 (en) | Human parainfluenza viruses having separated p and c genes | |
| Attenuated | Recombinant Respiratory Syncytial Virus |